| http://dbpedia.org/ontology/abstract
|
فيلوكسازين أوكما يًباع تحت الأسماء التجاري … فيلوكسازين أوكما يًباع تحت الأسماء التجارية فيفالان أو إيموفيت أو فيفارنت أوفيسيلان هو مشتق من المورفالين وهو مثبط انتقائي لاستعادة امتصاص النورإبينفرين. ويُستخدم كمضاد للاكتئاب في بعض الدول الأوروبية، وينتج تأثيرًا محفزًا مشابهًا للأمفيتامينات، وعلى عدم وجود أي آثار إدمانية. اكتُشف الدواء وخرج للأسواق في عام 1976 على يد شركة إمبريال للتصنيعات الدوائية وتم سحبه من السوق في أوائل عام 2000 لأسباب تجارية. من السوق في أوائل عام 2000 لأسباب تجارية.
, Viloxazine, sold under the brand name Qelb … Viloxazine, sold under the brand name Qelbree and formerly as Vivalan among others, is a noradrenergic medication which is used in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults. It was marketed for almost 30 years as an antidepressant for the treatment of depression before being discontinued and subsequently repurposed as a treatment for ADHD. Viloxazine is taken by mouth. It was used as an antidepressant in an immediate-release form and is used in ADHD in an extended-release form. Side effects of viloxazine include insomnia, headache, somnolence, fatigue, nausea, vomiting, decreased appetite, dry mouth, constipation, irritability, increased heart rate, and increased blood pressure. Rarely, the medication may cause suicidal thoughts and behaviors. It can also activate mania or hypomania in people with bipolar disorder. Viloxazine acts as a selective norepinephrine reuptake inhibitor (NRI). The immediate-release form has an elimination half-life of 2.5 hours while the half-life of the extended-release form is 7 hours. Viloxazine was first described by 1972 and was marketed as an antidepressant in Europe in 1974. It was not marketed in the United States at this time. The medication was discontinued in 2002 due to commercial reasons. However, it was repurposed for the treatment of ADHD and was reintroduced, in the United States, in April 2021. Viloxazine is a non-stimulant medication; it has no known misuse liability and is not a controlled substance.ability and is not a controlled substance.
, Viloxazin ist ein Selektiver Noradrenalin- … Viloxazin ist ein Selektiver Noradrenalin-Wiederaufnahmehemmer (NARI). Es wurde vom Pharmakonzern AstraZeneca entwickelt und 1976 als Vivalan auf den Markt gebracht zur Behandlung von Depressionen. Off-Label fand es auch Anwendung bei Enuresis und Narkolepsie. Im Juli 2006 wurde Vivalan vom Markt genommen. Seit April 2021 ist die Substanz als Qelbree in den USA zugelassen zur Behandlung der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) bei Kindern im Alter von 6 bis 17 Jahren. Das Morpholinderivat Viloxazin ähnelt von der chemischen Struktur her Betablockern, zählt aber zu den Antidepressiva. Das Racemat besteht aus dem (S)-(−)- und dem (R)-(+)-Enantiomer, wobei das (S)-(−)-Enantiomer eine fünfmal stärkere pharmakologische Wirkung hat.mal stärkere pharmakologische Wirkung hat.
, La viloxazina (Vivalan, Emovit, Vivarint, … La viloxazina (Vivalan, Emovit, Vivarint, Vicilan) è un farmaco antidepressivo biciclico che agisce come un inibitore selettivo del reuptake della norepinefrina (NRI). È un composto racemico con due stereoisomeri, di cui l'(S)-(–)-isomero è circa cinque volte più attivo dell' R)-(+)-isomero.que volte più attivo dell' R)-(+)-isomero.
, Viloxazina é um fármaco antidepressivo bic … Viloxazina é um fármaco antidepressivo bicíclico. É um derivado da morfolina e é um inibidor seletivo de recaptação de noradrenalina. Foi utilizado como um antidepressivo em alguns países europeus, e produziu um efeito estimulante que é semelhante às anfetaminas, exceto por estarem ausentes sinais de dependência. Foi descoberto e introduzido no mercado em 1976 pela Imperial Chemical Industries e foi retirado do mercado no início dos anos 2000, por razões comerciais.ício dos anos 2000, por razões comerciais.
|
| http://dbpedia.org/ontology/alternativeName
|
Qelbree, Vivalan, Emovit, others
|
| http://dbpedia.org/ontology/casNumber
|
35604-67-2
, 46817-91-8
|
| http://dbpedia.org/ontology/chEBI
|
94405
|
| http://dbpedia.org/ontology/chEMBL
|
306700
, 2106483
|
| http://dbpedia.org/ontology/class
|
http://dbpedia.org/resource/Norepinephrine_reuptake_inhibitor +
, http://dbpedia.org/resource/Antidepressant +
|
| http://dbpedia.org/ontology/drugbank
|
DB09185
, DBSALT001262
|
| http://dbpedia.org/ontology/fdaUniiCode
|
OQW30I1332
, 5I5Y2789ZF
|
| http://dbpedia.org/ontology/kegg
|
D02572
, D08673
|
| http://dbpedia.org/ontology/pubchem
|
5666
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Viloxazine_structure.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
https://druginfo.nlm.nih.gov/drugportal/name/viloxazine +
|
| http://dbpedia.org/ontology/wikiPageID
|
2177300
|
| http://dbpedia.org/ontology/wikiPageLength
|
28588
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1121072459
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Increased_blood_pressure +
, http://dbpedia.org/resource/UGT2B15 +
, http://dbpedia.org/resource/Modified-release_dosage +
, http://dbpedia.org/resource/Alcoholism +
, http://dbpedia.org/resource/Headache +
, http://dbpedia.org/resource/Indication_%28medicine%29 +
, http://dbpedia.org/resource/UDP-glucuronosyltransferase +
, http://dbpedia.org/resource/Kidney +
, http://dbpedia.org/resource/Insomnia +
, http://dbpedia.org/resource/Binding_selectivity +
, http://dbpedia.org/resource/Racemic_mixture +
, http://dbpedia.org/resource/Phases_of_clinical_research +
, http://dbpedia.org/resource/Phenytoin +
, http://dbpedia.org/resource/Transaminase +
, http://dbpedia.org/resource/Urine +
, http://dbpedia.org/resource/Rapid_eye_movement_sleep +
, http://dbpedia.org/resource/Nausea +
, http://dbpedia.org/resource/Increased_heart_rate +
, http://dbpedia.org/resource/Attention-Deficit/Hyperactivity_Disorder_Investigator_Symptom_Rating_Scale +
, http://dbpedia.org/resource/Steady-state_%28pharmacology%29 +
, http://dbpedia.org/resource/Erythrocyte +
, http://dbpedia.org/resource/Agonist +
, http://dbpedia.org/resource/Monoamine_transporter +
, http://dbpedia.org/resource/Fatigue_%28medical%29 +
, http://dbpedia.org/resource/Constipation +
, http://dbpedia.org/resource/Category:Norepinephrine_reuptake_inhibitors +
, http://dbpedia.org/resource/Attention_deficit_hyperactivity_disorder +
, http://dbpedia.org/resource/Metabolism +
, http://dbpedia.org/resource/Extensive_metabolizer +
, http://dbpedia.org/resource/Hypomania +
, http://dbpedia.org/resource/Blood_brain_barrier +
, http://dbpedia.org/resource/Poor_metabolizer +
, http://dbpedia.org/resource/Seizure +
, http://dbpedia.org/resource/Muscarinic_acetylcholine_receptor +
, http://dbpedia.org/resource/Feces +
, http://dbpedia.org/resource/Randomized_controlled_trial +
, http://dbpedia.org/resource/Elimination_%28pharmacology%29 +
, http://dbpedia.org/resource/Elimination_half-life +
, http://dbpedia.org/resource/Vertigo_%28medical%29 +
, http://dbpedia.org/resource/Hypotension +
, http://dbpedia.org/resource/Beta_blockers +
, http://dbpedia.org/resource/%CE%911-adrenergic_receptor +
, http://dbpedia.org/resource/Category:AstraZeneca_brands +
, http://dbpedia.org/resource/5-HT2A_receptor +
, http://dbpedia.org/resource/5-HT1A_receptor +
, http://dbpedia.org/resource/Cataplexy +
, http://dbpedia.org/resource/Category:Morpholines +
, http://dbpedia.org/resource/Placebo +
, http://dbpedia.org/resource/Metabolite +
, http://dbpedia.org/resource/Electrocardiogram +
, http://dbpedia.org/resource/Morpholine +
, http://dbpedia.org/resource/Glucuronidation +
, http://dbpedia.org/resource/Tremor +
, http://dbpedia.org/resource/Immediate-release +
, http://dbpedia.org/resource/Narcolepsy +
, http://dbpedia.org/resource/Blood_plasma +
, http://dbpedia.org/resource/Antidepressant +
, http://dbpedia.org/resource/Serotonin_reuptake_inhibitor +
, http://dbpedia.org/resource/Cmax_%28pharmacology%29 +
, http://dbpedia.org/resource/Pharmacodynamics +
, http://dbpedia.org/resource/Suicidal_ideation +
, http://dbpedia.org/resource/Excretion +
, http://dbpedia.org/resource/Side_effect +
, http://dbpedia.org/resource/Hydroxylation +
, http://dbpedia.org/resource/Receptor_antagonist +
, http://dbpedia.org/resource/Misuse_liability +
, http://dbpedia.org/resource/Norepinephrine_reuptake_inhibitor +
, http://dbpedia.org/resource/Extended-release +
, http://dbpedia.org/resource/Decreased_appetite +
, http://dbpedia.org/resource/Electroencephalogram +
, http://dbpedia.org/resource/Norepinephrine_transporter +
, http://dbpedia.org/resource/Dry_mouth +
, http://dbpedia.org/resource/Noradrenergic +
, http://dbpedia.org/resource/H1_receptor +
, http://dbpedia.org/resource/Serotonin_transporter +
, http://dbpedia.org/resource/Affinity_%28pharmacology%29 +
, http://dbpedia.org/resource/Tmax_%28pharmacology%29 +
, http://dbpedia.org/resource/Imperial_Chemical_Industries +
, http://dbpedia.org/resource/Receptor_%28biochemistry%29 +
, http://dbpedia.org/resource/Depression_%28mood%29 +
, http://dbpedia.org/resource/Category:Phenol_ethers +
, http://dbpedia.org/resource/Dopamine_transporter +
, http://dbpedia.org/resource/5-HT7_receptor +
, http://dbpedia.org/resource/5-HT2C_receptor +
, http://dbpedia.org/resource/Nocturnal_enuresis +
, http://dbpedia.org/resource/Irritability +
, http://dbpedia.org/resource/Epigastric_pain +
, http://dbpedia.org/resource/Bioavailability +
, http://dbpedia.org/resource/Racemic +
, http://dbpedia.org/resource/Theophylline +
, http://dbpedia.org/resource/Capsule_%28pharmacy%29 +
, http://dbpedia.org/resource/UGT1A9 +
, http://dbpedia.org/resource/Oral_administration +
, http://dbpedia.org/resource/Category:Attention_deficit_hyperactivity_disorder_management +
, http://dbpedia.org/resource/Pharmacologically +
, http://dbpedia.org/resource/Histamine_receptor +
, http://dbpedia.org/resource/Amisulpride +
, http://dbpedia.org/resource/CYP2D6 +
, http://dbpedia.org/resource/Plasma_protein_binding +
, http://dbpedia.org/resource/Mania +
, http://dbpedia.org/resource/Edema +
, http://dbpedia.org/resource/Cytochrome_P450 +
, http://dbpedia.org/resource/Non-stimulant +
, http://dbpedia.org/resource/Stereoisomer +
, http://dbpedia.org/resource/%CE%922-adrenergic_receptor +
, http://dbpedia.org/resource/5-HT2B_receptor +
, http://dbpedia.org/resource/Category:Antidepressants +
, http://dbpedia.org/resource/Antidiuretic_hormone +
, http://dbpedia.org/resource/Chemical_compound +
, http://dbpedia.org/resource/Serotonin_receptor +
, http://dbpedia.org/resource/Category:5-HT2B_antagonists +
, http://dbpedia.org/resource/Dopamine_receptor +
, http://dbpedia.org/resource/%CE%912-adrenergic_receptor +
, http://dbpedia.org/resource/%CE%911B-adrenergic_receptor +
, http://dbpedia.org/resource/Dysarthria +
, http://dbpedia.org/resource/Category:5-HT2C_agonists +
, http://dbpedia.org/resource/D2_receptor +
, http://dbpedia.org/resource/Category:Withdrawn_drugs +
, http://dbpedia.org/resource/Ethanolamine +
, http://dbpedia.org/resource/Suicidal_behavior +
, http://dbpedia.org/resource/Major_depressive_disorder +
, http://dbpedia.org/resource/Vomiting +
, http://dbpedia.org/resource/Dysthymia +
, http://dbpedia.org/resource/Bipolar_disorder +
, http://dbpedia.org/resource/ADHD +
, http://dbpedia.org/resource/Somnolence +
, http://dbpedia.org/resource/Controlled_substance +
, http://dbpedia.org/resource/Enzyme +
|
| http://dbpedia.org/property/atcPrefix
|
N06
|
| http://dbpedia.org/property/atcSuffix
|
AX09
|
| http://dbpedia.org/property/c
|
13
|
| http://dbpedia.org/property/casNumber
|
46817
, 35604
|
| http://dbpedia.org/property/chebi
|
94405
|
| http://dbpedia.org/property/chembl
|
2106483
, 306700
|
| http://dbpedia.org/property/chemspiderid
|
5464
, 64514
|
| http://dbpedia.org/property/chirality
|
http://dbpedia.org/resource/Racemic_mixture +
|
| http://dbpedia.org/property/class
|
http://dbpedia.org/resource/Antidepressant +
, http://dbpedia.org/resource/Norepinephrine_reuptake_inhibitor +
|
| http://dbpedia.org/property/dailymedid
|
Viloxazine
|
| http://dbpedia.org/property/drugbank
|
DB09185
, DBSALT001262
|
| http://dbpedia.org/property/eliminationHalfLife
|
-18000.0
, 17064.000000000004
|
| http://dbpedia.org/property/excretion
|
http://dbpedia.org/resource/Feces +
, http://dbpedia.org/resource/Urine +
|
| http://dbpedia.org/property/h
|
19
|
| http://dbpedia.org/property/image
|
Viloxazine molecule spacefill.png
|
| http://dbpedia.org/property/index2Label
|
HCl
|
| http://dbpedia.org/property/iupacName
|
-2
|
| http://dbpedia.org/property/kegg
|
D02572
, D08673
|
| http://dbpedia.org/property/legalUs
|
Rx-only
|
| http://dbpedia.org/property/metabolism
|
Hydroxylation , glucuronidation
|
| http://dbpedia.org/property/metabolites
|
5
|
| http://dbpedia.org/property/n
|
1
|
| http://dbpedia.org/property/o
|
3
|
| http://dbpedia.org/property/proteinBound
|
76
|
| http://dbpedia.org/property/pubchem
|
5666
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Oral_administration +
|
| http://dbpedia.org/property/smiles
|
CCOC1=CC=CC=C1OCC1CNCCO1
, Cl.CCOC1=CC=CC=C1OCC1CNCCO1
|
| http://dbpedia.org/property/stdinchi
|
1
|
| http://dbpedia.org/property/stdinchikey
|
YWPHCCPCQOJSGZ-UHFFFAOYSA-N
, HJOCKFVCMLCPTP-UHFFFAOYSA-N
|
| http://dbpedia.org/property/synonyms
|
ICI-58834; SPN-812; SPN-809
|
| http://dbpedia.org/property/tradename
|
Qelbree, Vivalan, Emovit, others
|
| http://dbpedia.org/property/unii
|
OQW30I1332
, 5
|
| http://dbpedia.org/property/verifiedfields
|
changed
|
| http://dbpedia.org/property/verifiedrevid
|
470630208
|
| http://dbpedia.org/property/watchedfields
|
changed
|
| http://dbpedia.org/property/width
|
175
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Rp +
, http://dbpedia.org/resource/Template:Stimulants +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Drugbox +
, http://dbpedia.org/resource/Template:Cascite +
, http://dbpedia.org/resource/Template:Serotonin_receptor_modulators +
, http://dbpedia.org/resource/Template:Chemspidercite +
, http://dbpedia.org/resource/Template:Ebicite +
, http://dbpedia.org/resource/Template:Antidepressants +
, http://dbpedia.org/resource/Template:Abbr +
, http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:ADHD_pharmacotherapies +
, http://dbpedia.org/resource/Template:Portal_bar +
, http://dbpedia.org/resource/Template:Nbsp +
, http://dbpedia.org/resource/Template:TOC_limit +
, http://dbpedia.org/resource/Template:Keggcite +
, http://dbpedia.org/resource/Template:ClinicalTrialsGov +
, http://dbpedia.org/resource/Template:Drugbankcite +
, http://dbpedia.org/resource/Template:Cite_web +
, http://dbpedia.org/resource/Template:Monoamine_reuptake_inhibitors +
, http://dbpedia.org/resource/Template:Stdinchicite +
, http://dbpedia.org/resource/Template:Abbrlink +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Antidepressants +
, http://dbpedia.org/resource/Category:5-HT2B_antagonists +
, http://dbpedia.org/resource/Category:Phenol_ethers +
, http://dbpedia.org/resource/Category:AstraZeneca_brands +
, http://dbpedia.org/resource/Category:5-HT2C_agonists +
, http://dbpedia.org/resource/Category:Attention_deficit_hyperactivity_disorder_management +
, http://dbpedia.org/resource/Category:Norepinephrine_reuptake_inhibitors +
, http://dbpedia.org/resource/Category:Withdrawn_drugs +
, http://dbpedia.org/resource/Category:Morpholines +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Inhibitor +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Viloxazine?oldid=1121072459&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Viloxazine_molecule_spacefill.png +
, http://commons.wikimedia.org/wiki/Special:FilePath/Viloxazine_structure.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Viloxazine +
|
| owl:sameAs |
http://dbpedia.org/resource/Viloxazine +
, http://pt.dbpedia.org/resource/Viloxazina +
, http://ar.dbpedia.org/resource/%D9%81%D9%8A%D9%84%D9%88%D9%83%D8%B3%D8%A7%D8%B2%D9%8A%D9%86 +
, http://rdf.freebase.com/ns/m.06sn9d +
, http://yago-knowledge.org/resource/Viloxazine +
, http://de.dbpedia.org/resource/Viloxazin +
, http://www.wikidata.org/entity/Q907148 +
, http://it.dbpedia.org/resource/Viloxazina +
, https://global.dbpedia.org/id/54JPy +
, http://sr.dbpedia.org/resource/Viloksazin +
, http://sh.dbpedia.org/resource/Viloksazin +
, http://fa.dbpedia.org/resource/%D9%88%DB%8C%D9%84%D9%88%DA%A9%D8%B3%D8%A7%D8%B2%DB%8C%D9%86 +
, http://ro.dbpedia.org/resource/Viloxazin%C4%83 +
|
| rdf:type |
http://dbpedia.org/class/yago/Antidepressant102718811 +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/class/yago/CausalAgent100007347 +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://dbpedia.org/class/yago/WikicatAntidepressants +
, http://dbpedia.org/class/yago/Drug103247620 +
, http://dbpedia.org/class/yago/Agent114778436 +
, http://dbpedia.org/class/yago/WikicatBicyclicAntidepressants +
, http://dbpedia.org/class/yago/Medicine103740161 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/Substance100020090 +
, http://www.wikidata.org/entity/Q8386 +
|
| rdfs:comment |
Viloxazina é um fármaco antidepressivo bic … Viloxazina é um fármaco antidepressivo bicíclico. É um derivado da morfolina e é um inibidor seletivo de recaptação de noradrenalina. Foi utilizado como um antidepressivo em alguns países europeus, e produziu um efeito estimulante que é semelhante às anfetaminas, exceto por estarem ausentes sinais de dependência. Foi descoberto e introduzido no mercado em 1976 pela Imperial Chemical Industries e foi retirado do mercado no início dos anos 2000, por razões comerciais.ício dos anos 2000, por razões comerciais.
, Viloxazine, sold under the brand name Qelb … Viloxazine, sold under the brand name Qelbree and formerly as Vivalan among others, is a noradrenergic medication which is used in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults. It was marketed for almost 30 years as an antidepressant for the treatment of depression before being discontinued and subsequently repurposed as a treatment for ADHD. Viloxazine is taken by mouth. It was used as an antidepressant in an immediate-release form and is used in ADHD in an extended-release form. used in ADHD in an extended-release form.
, Viloxazin ist ein Selektiver Noradrenalin- … Viloxazin ist ein Selektiver Noradrenalin-Wiederaufnahmehemmer (NARI). Es wurde vom Pharmakonzern AstraZeneca entwickelt und 1976 als Vivalan auf den Markt gebracht zur Behandlung von Depressionen. Off-Label fand es auch Anwendung bei Enuresis und Narkolepsie. Im Juli 2006 wurde Vivalan vom Markt genommen. Seit April 2021 ist die Substanz als Qelbree in den USA zugelassen zur Behandlung der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) bei Kindern im Alter von 6 bis 17 Jahren. bei Kindern im Alter von 6 bis 17 Jahren.
, فيلوكسازين أوكما يًباع تحت الأسماء التجاري … فيلوكسازين أوكما يًباع تحت الأسماء التجارية فيفالان أو إيموفيت أو فيفارنت أوفيسيلان هو مشتق من المورفالين وهو مثبط انتقائي لاستعادة امتصاص النورإبينفرين. ويُستخدم كمضاد للاكتئاب في بعض الدول الأوروبية، وينتج تأثيرًا محفزًا مشابهًا للأمفيتامينات، وعلى عدم وجود أي آثار إدمانية. اكتُشف الدواء وخرج للأسواق في عام 1976 على يد شركة إمبريال للتصنيعات الدوائية وتم سحبه من السوق في أوائل عام 2000 لأسباب تجارية. من السوق في أوائل عام 2000 لأسباب تجارية.
, La viloxazina (Vivalan, Emovit, Vivarint, … La viloxazina (Vivalan, Emovit, Vivarint, Vicilan) è un farmaco antidepressivo biciclico che agisce come un inibitore selettivo del reuptake della norepinefrina (NRI). È un composto racemico con due stereoisomeri, di cui l'(S)-(–)-isomero è circa cinque volte più attivo dell' R)-(+)-isomero.que volte più attivo dell' R)-(+)-isomero.
|
| rdfs:label |
Viloxazina
, Viloxazine
, فيلوكسازين
, Viloxazin
|
